Intravenous (IV) Iron Drugs market projected to reach global value of US$1.6 billion by 2018, driven by aging population, rising incidences of chronic kidney disease (CKD), increasing number of patients on dialysis, and unresponsive oral therapies in many patients.
The Intravenous (IV) Iron Drugs market is witnessing strong growth driven by widespread iron deficiency anemia as a result of diseases related to oncology, gynecology, gastroenterology and nephrology. Iron deficiency anemia (IDA) is recognized as a debilitating nutritional deficiency affecting approximately 2.0 billion individuals worldwide. The condition is particularly high in patients suffering from Chronic Kidney Disease (CKD), a condition which is increasingly becoming a burden to healthcare systems worldwide.
Major factors driving the prevalence of CKD include aging world population and increasing prevalence of conditions such as, diabetes, obesity, heart disease, stroke, etc., that are known to be risk factors for CKD. Nephrology remains a major market for IV iron therapies. Despite the high prevalence of CKD, only a fraction of the total afflicted patients undergo treatment through IV iron therapies, thereby presenting huge untapped potential for growth.
While the use of IV iron therapies is dialysis is well established, limitations in diagnosis have historically prevented significant use of IV iron in other therapeutic areas. Global market for intravenous (IV) iron therapies, dominated hitherto by the field of nephrology, however, is expected to witness a sea-change with the need to address IDA in other chronic illnesses and in patients not responding to oral iron therapies. Intravenous iron drugs have evolved over the years with first-generation preparations, known to induce serious anaphylactic reactions, making way for second and third-generations intravenous iron preparations with demonstrated safety and efficacy profiles.
Oral iron, the most commonly used therapy in broader iron deficiency anemia patients (outside nephrology) is limited by the inability of patients to respond to the treatment. Patients are often required to continue therapy for extended period of time, up to 6 months in some cases, resulting in high rates of discontinuation of therapy, particularly among patients experiencing adverse effects such as fatigue and nausea. The limitations of oral iron therapy further expand the scope for intravenous (IV) iron, especially second and third generation compounds developed to correct IDA with minimal side effects. Concerns over adverse reactions to nearly all IV iron preparations; and serious anaphylactic reactions in the case of iron dextran preparations, is the most significant factor promoting further research for developing safe and effective IV iron drugs.
The United States represents the single largest market worldwide. Rising obesity levels, the subsequent increase in diabetes, and an ageing population add to the rise in risk for CKD, the primary factor driving demand for intravenous iron drugs in the country. Additionally, the market is also benefiting from the rising evidence of the benefits of IV iron over oral iron drugs. Asia-Pacific is forecast to spearhead future growth led by growing population and rising incidence of chronic kidney disease (CKD). The region is projected to register a compounded annual growth rate of 12.4% over the analysis period.